BridgeBio Pharma, Inc. 8-K

What Happened
BridgeBio Pharma, Inc. filed an 8-K on January 12, 2026 announcing preliminary, unaudited financial information and issuing a press release. The company estimated it had approximately $587.5 million in cash, cash equivalents and marketable securities as of December 31, 2025, and reported estimated net product revenue of $146.0 million for the quarter ended December 31, 2025 and $362.4 million for the fiscal year ended December 31, 2025. On the same date BridgeBio presented a business update at the 44th Annual J.P. Morgan Healthcare Conference; the presentation slides were posted to the company website and filed as Exhibit 99.2.

Key Details

• Preliminary cash, cash equivalents and marketable securities: approximately $587.5 million as of Dec 31, 2025.
• Estimated net product revenue: $146.0 million (Q4 2025) and $362.4 million (FY2025).
• Filing date and events: press release and 8-K filed Jan 12, 2026; JP Morgan presentation (44th Annual) slides filed as Exhibit 99.2 and press release as Exhibit 99.1.
• Figures are described as preliminary and unaudited; the filing includes customary forward-looking statements and risk disclosures.

Why It Matters
These preliminary figures give investors a near-term view of BridgeBio’s liquidity and recent commercial revenue trends, which are key for assessing cash runway and the company's progress commercializing its products. Because the numbers are preliminary and unaudited, investors should watch for the company’s regular earnings release and audited financial statements for final results. The JP Morgan presentation provides additional context on the company’s pipeline, regulatory plans and assumptions, but the filing reiterates the usual forward-looking statement cautions and risks.